EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltration

Margarite D Matossian, Christine Shiang, Deniz Nesli Dolcen, Marie Dreyer, Ken Hatogai, Katie Hall, Poornima Saha, Anna Biernacka, Randy F Sweis, Theodore Karrison, Nan Chen, Rita Nanda und 1 weitere

Breast Cancer Research and Treatment · 2025-02 · 209 (3) · 563-572

DOI: 10.1007/s10549-024-07515-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, online erschienen am 23.11.2024. Verfasst von Margarite D Matossian und 12 weiteren Autor:innen. Beteiligte Einrichtung: Section of Hematology and Oncology, Department of Medicine, The University of Chicago, Chicago, IL, 60637, USA. Hauptthemen laut MEDLINE: Receptors, Glucocorticoid, Triple Negative Breast Neoplasms, T-Lymphocytes, Regulatory, Lymphocytes, Tumor-Infiltrating. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIH HHS, Cancer Prevention and Research Institute of Texas.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: In early-stage, triple-negative breast cancer (TNBC), immune cell infiltration contributes to cancer cell survival, tumor invasion, and metastasis. High TNBC glucocorticoid receptor (GR) expression in early-stage TNBC is associated with poor long-term outcomes; it is unknown if high GR expression is associated with an immunosuppressed tumor microenvironment. We hypothesized that high tumor GR expression would be associated with an immune-suppressed tumor microenvironment, which could thus account for the poor prognosis observed in GR-positive TNBC. METHODS: Formalin fixed-paraffin embedded tissue (n = 47) from patients diagnosed with early-stage TNBC from The University of Chicago (2002-2014) were evaluated for both tumor cell anti-GR immunohistochemistry and for infiltrating immune cells by immunofluorescence. Multiplexed antibodies were used to enumerate CD8+, FOXP3+, and BATF3+ immune cells infiltrating within pan-cytokeratin positive tumor cell regions of interest, and nonparametric tests compared absolute counts of each of these tumor-infiltrating immune cell types. RESULTS: The average age of patients represented in this study was 52 years, and 63% self-identified as Black. There was no significant association between tumor GR expression and age, race, or clinical stage at diagnosis. Compared to GR-low tumors, high GR expression in early-stage, treatment-naïve TNBC was associated with relatively increased numbers of immunosuppressive FOXP3 + regulatory T cells (p = 0.046) and BATF3+immune cells (p = 0.021). While there was a positive correlation with high GR expression and CD8+ cell infiltration, it was not significant (p = 0.068). The ratio of CD8+/FOXP3+cells was also not significant (p = 0.24). CONCLUSIONS: These data support the hypothesis that in early-stage TNBC, high GR expression is significantly associated with infiltration of immunosuppressive regulatory T cells, suggesting a tumor-intrinsic role in shaping the immunosuppressive immune cell milieu. Furthermore, suppression of GR activity may regulate the tumor immune microenvironment and improve long-term outcomes in GR-high TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, GlucocorticoidTriple Negative Breast NeoplasmsT-Lymphocytes, RegulatoryLymphocytes, Tumor-InfiltratingHumansFemaleMiddle AgedNeoplasm StagingTumor MicroenvironmentAdultAgedPrognosisBiomarkers, TumorImmunohistochemistry

Stichwörter der Autor:innen

BATF3+CD8+cytotoxic T-cellsDendritic cellsFOXP3+Glucocorticoid receptor (GR)T-regulatory cellsTriple-negative breast cancer (TNBC)Tumor immune microenvironment

Substanzen

Receptors, GlucocorticoidBiomarkers, Tumor

Autor:innen und Institutionen

  • Section of Hematology and Oncology, Department of Medicine, The University of Chicago, Chicago, IL, 60637, USA.
  • Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
  • Department of Pathology, The University of Chicago, Chicago, IL, 60637, USA.
  • Division of Hematology and Oncology, Department of Medicine, Endeavor Health, Evanston, IL, 60201, USA.
  • Department of Public Health Sciences, The University of Chicago, Chicago, IL, 60637, USA.
  • Section of Hematology and Oncology, Department of Medicine, The University of Chicago, Chicago, IL, 60637, USA. rnanda@bsd.uchicago.edu.

Förderung

  • NCI NIH HHS
  • NIH HHS
  • Cancer Prevention and Research Institute of Texas
  • National Institutes of Health

Zitieren

APA

Matossian, M. D., Shiang, C., Dolcen, D. N., Dreyer, M., Hatogai, K., Hall, K., Saha, P., Biernacka, A., Sweis, R. F., Karrison, T., Chen, N., Nanda, R., & Conzen, S. D. (2025). High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltration. Breast Cancer Research and Treatment, 209(3), 563-572. https://doi.org/10.1007/s10549-024-07515-3

Vancouver

Matossian MD, Shiang C, Dolcen DN, Dreyer M, Hatogai K, Hall K, et al. High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltration. Breast Cancer Research and Treatment. 2025;209(3):563-572. doi:10.1007/s10549-024-07515-3

BibTeX
@article{Matossian2025,
  author = {Matossian, Margarite D and Shiang, Christine and Dolcen, Deniz Nesli and Dreyer, Marie and Hatogai, Ken and Hall, Katie and Saha, Poornima and Biernacka, Anna and Sweis, Randy F and Karrison, Theodore and Chen, Nan and Nanda, Rita and Conzen, Suzanne D},
  title = {High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltration},
  journal = {Breast Cancer Research and Treatment},
  year = {2025},
  volume = {209},
  number = {3},
  pages = {563--572},
  doi = {10.1007/s10549-024-07515-3}
}
Kostenlos starten →